In a recently published study in The Journal of Headache and Pain, Italian researchers compiled data on 548 patients suffering from chronic and episodic migraines enrolled in a tertiary level headache center to determine overall costs incurred.
In a recently published study in The Journal of Headache and Pain, Italian researchers compiled data on 548 patients suffering from chronic and episodic migraines enrolled in a tertiary level headache center to determine overall costs incurred.
Authors concluded that costs were significantly higher for women with migraine than men ($1693.86 [€1517] vs $1422.53 [€1274]; P = .013), and that costs resulting from migraine treatment increased as the patient got older (P = .0002).
“The main item of expenditure were medications that represented 86.8%” of the total costs, researchers said. Medications were followed by “specialist visits (10.2%), hospitalizations for (1.9%), diagnostic tests for (1%) and emergency department visits for (0.1%).” The mean annual cost of medications was $1435.93 (€1286), and preventive treatments accounted for the majority of this cost at $1222.66 (€1095).
In addition, the annual direct cost incurred by patients with chronic migraine (CM) was 4.8-fold higher than those with episodic migraine (EM) ($2278.56 [€2037] vs $477.64 [€427]; P = .0001).
Italy’s National Health Service (NHS) covered the majority of costs of patients with migraines. Of the average annual expenditure per patient ($1656.58 [€1482]), the NHS covered 82.8% of the total cost, or $1371.55 (€1227). Patients had an annual personal expenditure of $284.73 (€255).
Migraine affects around 1.4 billion people worldwide and, according to the Global Burden of Diseases, it is the second cause of years of life lived with disability in the world. Direct cost of the disease is difficult to pin down due to the numerous comorbidities often associated with CM and the fact that many patients with migraine never approach their physician about the disease.
However, researchers aimed to work around the barriers by conducting this retrospective and noninterventional observational analysis.
Data from patients’ electronic medical records were collected and only patients with EM and CM who underwent continuous treatment in the 2 years prior to January 2019 while at the Regional Referral Headache Center of Rome were included in the study. This methodology was used to “prevent distortions due to natural fluctuations in migraine status over time.” Researchers also stated that by following this method, “it was possible to detect any changes in dosage and class of drugs and, therefore, provide better estimates of the cost of pharmacological treatments.”
Researchers used the parameters outlined in the third edition of the International Classification of Headache Disorders, which “set the threshold for differentiating EM from CM at 15 days per month in the last 3 months.” The cross-sectional cost-of-illness evaluation also included demographic characteristics, the number of specialist visits and diagnostic tests, along with “accesses in the emergency department and days of hospitalization resulting from pathology and consumption of medications.”
Reference
Negro A, Sciattella P, Rossi D, Guglielmetti M, Martelletti P, Mennini FS. Cost of chronic and episodic migraine patients in continuous treatment for two years in a tertiary level headache center. J Headache Pain. 2019;20(1):120. doi: 10.1186/s10194-019-1068-y.
What We’re Reading: Historic Low of Uninsured; Youth Gender Treatments; Birth Control Recall
August 4th 2023A record low of 7.7% of Americans had no health insurance at the start of 2023; the American Academy of Pediatrics renewed its backing of gender care for children while requesting a research review; 2 lots of an oral contraceptive were recalled for possible reduction in effectiveness.
Read More
Addressing Maternal Mortality in Medicaid by Focusing on Mental Health
February 15th 2023On this episode of Managed Care Cast, we speak with Inland Empire Health Plan, a managed care plan serving more than 1.4 million residents on Medi-Cal in California, about a new maternal mental health program aimed at supporting new mothers, both before they give birth and afterward.
Listen
Prior Authorization Requirements for Calcitonin Gene-Related Peptide Antagonists
April 20th 2023This quantitative and qualitative analysis highlights differences in prior authorization requirements for migraine drugs from nearly 50 managed care organizations and summarizes broad types of criteria used.
Read More
For National Women’s Health Week, One Company Emphasizes Cardiovascular Risk Management
May 10th 2022On this episode of Managed Care Cast, we speak with Joanne Armstrong, MD, MPH, vice president and chief medical officer for Women’s Health and Genomics at CVS Health, on the distinct pathophysiology of cardiovascular disease in women and how her own health experiences have influenced her perspective on cardiovascular disease management.
Listen
Pregnant Women With Epilepsy Experience Worse Perinatal Outcomes
March 15th 2023Findings of a meta-analysis showed that women with epilepsy were at increased odds of miscarriage, stillbirth, and maternal death, and risk of poor perinatal outcomes increased with greater use of antiseizure medication.
Read More